Detection of Novel Biallelic Causative Variants in COL7A1 Gene by Whole-Exome Sequencing, Resulting in Congenital Recessive Dystrophic Epidermolysis Bullosa in Three Unrelated Families.
PMID:35885431
Genetic Profile of Epidermolysis Bullosa Cases in King Abdulaziz Medical City, Riyadh, Saudi Arabia.
PMID:35222512
Chronic Ulcers and Malnutrition in an African Patient.
PMID:33115794
Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1.
PMID:33081018
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa.
PMID:31796084
Dystrophic Epidermolysis Bullosa.
PMID:31065125
Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair.
PMID:30195791
Recent advances in understanding and managing epidermolysis bullosa.
PMID:30057747
A multitask clustering approach for single-cell RNA-seq analysis in Recessive Dystrophic Epidermolysis Bullosa.
PMID:29630593
Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model.
PMID:28137859
Dental and Anaesthetic Challenges in a Patient with Dystrophic Epidermolysis Bullosa.
PMID:28003899
Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy.
PMID:27157667
Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial.
PMID:27015660
Treatment of feet deformities in epidermolysis bullosa.
PMID:26899603
Topical Collagen-Based Biomaterials for Chronic Wounds: Rationale and Clinical Application.
PMID:26858912
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms.
PMID:26194911
Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.
PMID:26073463
Dystrophic epidermolysis bullosa: a review.
PMID:26064063
Recessive dystrophic epidermolysis bullosa: a review of disease pathogenesis and update on future therapies.
PMID:26029334
Molecular architecture and function of the hemidesmosome.
PMID:26017636
From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.
PMID:25803200
Placenta-based therapies for the treatment of epidermolysis bullosa.
PMID:25795271
Molecular architecture and function of the hemidesmosome.
PMID:25487405
Epidermolysis bullosa and the partnership with autoimmunity: what should we assimilate?
PMID:25412732
Dystrophic epidermolysis bullosa in pregnancy: a case report of the autosomal dominant subtype and review of the literature.
PMID:24864146
Molecular identification of collagen 17a1 as a major genetic modifier of laminin gamma 2 mutation-induced junctional epidermolysis bullosa in mice.
PMID:24550734
Recommended strategies for epidermolysis bullosa management in romania.
PMID:24371486
Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa.
PMID:24317394
Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix.
PMID:24095195
Collagen VII plays a dual role in wound healing.
PMID:23867500
Inherited epidermolysis bullosa: clinical and therapeutic aspects.
PMID:23739692
Prioritization of therapy uncertainties in Dystrophic Epidermolysis Bullosa: where should research direct to? an example of priority setting partnership in very rare disorders.
PMID:23607806
X-linked ichthyosis along with epidermolysis bullosa.
PMID:22629078
Dystrophic epidermolysis bullosa in a child.
PMID:22557906
Folding delay and structural perturbations caused by type IV collagen natural interruptions and nearby Gly missense mutations.
PMID:22179614